Table 2 Study characteristics of studies investigating the prognostic relevance of HPV-18
Author | Year | Country | Total number of patients | Mean age | Clinical stage | Treatment | Number of patients with HPV-18 positive | Number of patients with HPV-18 negative | Median DFS | Median PFS | Median OS |
|---|---|---|---|---|---|---|---|---|---|---|---|
Yat Ming Lau | 2015 | Hong Kong, China | 236 | 54.4 | I-III | radiotherapy+/−chemotherapy. | 30 | 185 | 73.2% vs. 78.2%, HR: 1.49, 95% CI = 0.78–2.86 | NA | 80% vs. 75.7%, HR: 1.23, 95% CI = 0.66–2.27 |
Sun-Hye Yang | 2014 | Korea | 116 | NA | I-IIA | surgery | 15 | 101 | NA | HR: 5.2, 95% CI = 1.29–20.9, P = 0.02 | Not significant |
Rossana de Arau ́jo Cata ̃o Zampronha | 2013 | Brazil | 86 | 40 | I | Surgery+radiotherapy | 25 | 51 | HR: 0.797, 95% CI = 0.175–3.640 | NA | NA |
Robert A. Burger | 1996 | USA | 291 | NA | I-IV | radical hysterectomy and pelvic lymphadenectomy | 58 | 233 | NA | NA | HR: 2.59, 95% CI = 1.08–6.22 |
Chyong-Huey Lai | 2007 | Taiwan, China | 1067 | 50 | IA-IIA | surgery | 176 | 891 | HR: 1.8, 95% CI = 1.8–2.7 | HR: 1.7, 95% CI = 1.1–2.6 | |
Woo Dae Kang | 2011 | Korea | 204 | 49 | IB-IIA | radical hysterectomy followed by adjuvant radiotherapy or primary radiotherapy with concurrent cisplatin-containing chemotherapy | 28 | 176 | NA | HR: 2.664, 95% CI = 1.437–4.938 | NA |
Shizhuo Wang | 2012 | China | 24,041 | NA | I-IV | NA | 2082 | 21,959 | NA | NA | HR: 1.704, 95% CI = 1.095–2.654 |